Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

dimethyl fumarate

Details

Files
Generic Name:
dimethyl fumarate
Project Status:
Complete
Therapeutic Area:
Multiple Sclerosis (MS)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0751-000
Call for patient/clinician input closed:
NOC Status at Filing:
N/A
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
​Radiologically Isolated Syndrome (RIS).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Submission received11-Jul-24
Review initiated12-Jul-24
Expert committee meeting (initial)21-Nov-24
Draft recommendation posted for stakeholder feedback12-Dec-24
End of feedback period03-Jan-25
Final recommendation posted04-Feb-25
CADTH review report(s) posted29-Jan-25

Files

Recommendation and Reasons View PDF
Responses to the Questions From the Drug Programs View PDF
Clinical and Pharmacoeconomic Combined Report View PDF
Combined Report Supplemental Materials View PDF
Feedback on Draft Recommendation View PDF
Patient, Clinician and Industry Input View PDF
Last Updated : February 10, 2025